Immunoglobulin News and Research

RSS

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration.

24 Nov 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Hiroshima University researchers report promising new avenue for treating hepatitis B

A promising new avenue for treating hepatitis B has been reported by researchers at Hiroshima University who have developed a new animal model of the disease.

28 Oct 2015

Research provides leads for new strategies to develop HIV vaccine

Recent research has yielded new information about immune responses associated with--and potentially responsible for--protection from HIV infection, providing leads for new strategies to develop an HIV vaccine.

22 Oct 2015

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease.

12 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Sexual activity causes physiological changes in the body that increase women's chances of getting pregnant

Research from Indiana University has found that sexual activity triggers physiological changes in the body that increase a woman's chances of getting pregnant, even outside the window of ovulation.

6 Oct 2015

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Patients with autoimmune cerebellar ataxia have better treatment responses and outcomes if they have the nonparaneoplastic form of the condition and are seropositive for neural plasma membrane protein or glutamic acid decarboxylase 65 antibodies, suggests research.

29 Sep 2015

New cell type appears to drive life-threatening food allergies

Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.

22 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.

From Quest Diagnostics 4 Sep 2015

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.

3 Sep 2015

Research reveals why older adults who undergo general anesthesia experience postoperative delirium

Newly published research from the Department of Geriatrics and Gerontology at the Rowan University School of Osteopathic Medicine explains why up to half of older adults who undergo general anesthesia develop postoperative delirium - the sudden onset of confusion, aggression or agitated behavior that could progress to dementia. The findings indicate that older patients who are undergoing surgery may benefit from a less-potent, slower-acting anesthetic.

26 Aug 2015

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

20 Aug 2015

Scientists reveal how non-allergenic pollen mediators can increase allergic reactions

Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.

13 Aug 2015

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Half of patients referred to a specialist centre with a diagnosis of chronic inflammatory demyelinating polyneuropathy do not actually have the condition, report researchers.

5 Aug 2015

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months.

27 Jul 2015

Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.

17 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015